Recent progress in developing highly selective and potent CaMKK2 inhibitors and ligand-directed degraders [85–90] has advanced the field a step closer to realizing the therapeutic potential of targeting CaMKK2 for treating prostate cancer and other diseases associated with aberrant CaMKK2 activation, including Alzheimer’s disease and liver steatosis. This evidence concerns the gene CAMKK2 and Familial prostate cancer.